Findings

What do systematic reviews say?

9 questions · 9 findings · 4 reviews · Acute Respiratory Infections

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 11.1%GRADE not reported 2 · 22.2%Very low 1 · 11.1%Low 5 · 55.6%Moderate 0 · 0%High 0 · 0%

Vitamin A vs placebo

Adverse events · children up to the age of 7 at risk of upper respiratory tract infection

1 finding from 1 review

Oral vitamin A supplements to prevent acute upper respiratory tract infections in children up to seven years of age 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 116 participants
Very low

HFNC vs standard oxygen therapy

Adverse events · infants with bronchiolitis

Summary of findings table ‐ High‐flow nasal cannula showed no clear difference in adverse events compared with standard oxygen therapy (low‐flow) (low certainty).

1 finding from 1 review

High‐flow nasal cannula therapy for infants with bronchiolitis 2024 · Cochrane Headline outcomes only
RR 1.2 [0.38, 3.74]
4 studies · 1789 participants
Low

Immunoglobulin vs placebo

Serious adverse events · children with respiratory syncytial virus infection

Summary of findings table ‐ Immunoglobulins showed no clear difference in serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection 2023 · Cochrane Headline outcomes only
RR 1.08 [0.65, 1.79]
4 studies · 238 participants
Low

Immunoglobulin vs placebo

Adverse events of any severity or seriousness · children with respiratory syncytial virus infection

Summary of findings table ‐ Immunoglobulins showed no clear difference in adverse events of any severity or seriousness compared with placebo (low certainty).

1 finding from 1 review

Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection 2023 · Cochrane Headline outcomes only
RR 1.18 [0.78, 1.78]
5 studies · 340 participants
Low

Summary of findings for multi‐dose nasal decongestant vs placebo

Secondary outcome: all adverse events · adult patients with the common cold

Summary of findings for multi‐dose nasal decongestant showed no clear difference in secondary outcome: all adverse events compared with placebo (low certainty).

1 finding from 1 review

Nasal decongestants in monotherapy for the common cold 2016 · Cochrane Headline outcomes only
OR 0.98 [0.68, 1.4]
7 studies · 1195 participants
Low

Summary of findings for single‐dose nasal decongestant vs placebo

Secondary outcome: all adverse events · adult patients with the common cold

1 finding from 1 review

Nasal decongestants in monotherapy for the common cold 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 82 participants
GRADE not reported

Summary of findings for all doses of nasal decongestant vs placebo

Secondary outcome: all adverse events · adult patients with the common cold

The review found no eligible studies for this question.

1 finding from 1 review

Nasal decongestants in monotherapy for the common cold 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings for multi‐dose nasal decongestant vs placebo

Secondary outcome: all adverse eventsOral · adult patients with the common cold

Summary of findings for multi‐dose nasal decongestant showed no clear difference in secondary outcome: all adverse eventsOral compared with placebo (low certainty).

1 finding from 1 review

Nasal decongestants in monotherapy for the common cold 2016 · Cochrane Headline outcomes only
OR 0.95 [0.65, 1.39]
6 studies · 1134 participants
Low

Summary of findings for multi‐dose nasal decongestant vs placebo

Secondary outcome: all adverse eventsTopical · adult patients with the common cold

1 finding from 1 review

Nasal decongestants in monotherapy for the common cold 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 61 participants
GRADE not reported